IDH1 and glioblastoma: Due to higher prevalence of favorable mutations, such as the isocitrate dehydrogenase 1/2 (IDH1/2) gene mutations, the prognosis and survival for these patients are slightly better than for patients with de novo (primary) glioblastoma [35–37].